Contract Pharma Manufacturing News

  1. Intas Pharmaceuticals And Accord Biopharma Become One Of The Largest Global Suppliers Of Pegfilgrastim With Acquisition Of UDENYCA® 8/6/2025

    Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.

  2. WACKER And Gearbox Biosciences Announce Strategic Collaboration To Advance Plasmid DNA Manufacturing Technologies 8/6/2025

    High-quality pDNA serves as a foundational source of genetic information in the development of life-saving therapies, yet current manufacturing processes face challenges in terms of scalability, efficiency, and cost-effectiveness.

  3. Sumitomo Chemical Announces An Expansion Of The Production Capacity Of Its Regenerative Medicine And Cell Therapy CDMO Subsidiary 8/5/2025

    Sumitomo Chemical Co., Ltd. (“Sumitomo Chemical” or “the Company”) hereby announces that S-RACMO Co., Ltd. (“S-RACMO”), a subsidiary 66.6% owned by Sumitomo Chemical and 33.4% by Sumitomo Pharma, has completed construction of its third regenerative medicine and cell therapy manufacturing facility, known as CRAFT (*1) (“the Facility”). 

  4. CHO Plus Enters Into Project Agreement With BARDA's BioMaP Consortium To Develop High Productivity Cell Lines For Filovirus Monoclonal Antibody Production 8/5/2025

    Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) for up to $10.4M for developing high productivity Chinese hamster ovary cell lines for manufacturing filovirus monoclonal antibodies for therapeutic use over a 30-month period. The agreement has a base period and two option periods.

  5. Bio-Techne Announces Exosome Diagnostics Divestiture 8/5/2025

    Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets.

  6. ScaleReady Announces A G-Rex® Grant Has Been Awarded To Sidra Medicine 8/5/2025

    ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sidra Medicine, a women and children's hospital in Qatar, has been awarded a $100,000 G-Rex® Grant.

  7. Axplora Announces €6.5M Investment At Vizag Site And FDA Inspection Success Across Indian Operations 8/5/2025

    Axplora, a global leader in API small molecule manufacturing, today announced a significant investment at its Vizag site in India to expand production capacity and reinforce supply chain resilience.

  8. Minaris Advanced Therapies Opens New State-Of-The-Art GMP Facility To Support Global Cell And Gene Therapy Growth 8/4/2025

    Minaris Advanced Therapies, a leading global contract development and manufacturing organization and testing provider, has announced the opening of its new GMP manufacturing facility in Munich, Germany.

  9. WuXi XDC Achieves GMP Release Of Newly Launched DP3 Facility At Wuxi Site, Scaling Further Drug Product Manufacturing Capacity 8/4/2025

    WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the Drug Product 3 ("DP3") facility at the Wuxi site has completed GMP release at the end of July, signifying the company's relentless pursuit of excellence in capacity expansion and business growth.

  10. Alveolus Bio Secures Strategic Investment From Shilpa Medicare To Advance Groundbreaking Pulmonary Therapeutics 8/4/2025

    Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation.